Valuation : Berkley Renewables Inc.

Market Cap 4L 3L 3L 3L 5L 3.48Cr 5L 34.93L 13.63L 1.76Cr 13.68L 13.38L 5.83Cr P/E 2016
4.22x
P/E 2017 -1.16x
Enterprise Value 51.26L 44.17L 41.41L 37.8L 71.21L 49Cr 71.44L 4.91Cr 1.92Cr 25Cr 1.92Cr 1.88Cr 82Cr EV / Sales 2016
3.53x
EV / Sales 2017 3.18x
Free-Float
90.7%
Yield 2016 *
-
Yield 2017 -
Manager TitleAgeSince
Chief Executive Officer 63 20/06/2002
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 63 -
Director/Board Member 66 17/08/2006
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 5L
+0.64%-3.35%+31.71%+10.79% 16TCr
-1.29%-3.77%+56.68%+56.99% 10TCr
-0.80%-6.34%+14.85%+12.12% 7.52TCr
-0.12%-3.59%+24.13%-5.29% 5.91TCr
-0.07%-3.26%+92.25%+66.45% 5.83TCr
-1.42%-6.19%+32.88%+30.74% 5.54TCr
+0.49%-3.56%+31.16%-6.66% 5.44TCr
+0.84%-4.47%+22.19%-15.39% 4.4TCr
+0.57%-0.19%+39.95%+10.67% 3.4TCr
Average -0.12%-3.64%+38.42%+17.82% 6.38TCr
Weighted average by Cap. -0.15%-4.06%+38.34%+20.29%

Financials

2016 2017
Net sales 10.34L 9L 8L 8L 14.37L 9.88Cr 14.41L 99.12L 38.67L 4.99Cr 38.82L 37.98L 17Cr 17.25L 14.86L 13.93L 12.72L 23.96L 16Cr 24.04L 1.65Cr 64.5L 8.32Cr 64.76L 63.35L 28Cr
Net income 2L 1L 1L 1L 2L 1.65Cr 2L 16.55L 6L 83.32L 6L 6L 2.76Cr -6L -5L -5L -5L -9L -6.03Cr -9L -60.44L -23.58L -3.04Cr -23.67L -23.16L -10Cr
Net Debt 29.17L 25.14L 23.57L 21.51L 40.53L 28Cr 40.66L 2.8Cr 1.09Cr 14Cr 1.1Cr 1.07Cr 47Cr 47.61L 41.03L 38.47L 35.11L 66.15L 46Cr 66.36L 4.56Cr 1.78Cr 23Cr 1.79Cr 1.75Cr 76Cr
Logo Berkley Renewables Inc.
Berkley Renewables Inc. is a Canada-based, growth-oriented diversified issuer also pursuing renewable energy opportunities, primarily in the solar energy sector. The Company is pursuing solar energy investments in Ontario, Canada. It is also engaged in developing autologous cell therapies to treat conditions linked to a deficit of healthy cells required for normal healing and function through RepliCel Life Sciences Inc. The Company's RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin and pattern baldness. The Company is also developing a proprietary injection device (RCI) for optimal clinical delivery. The Company is developing solar photovoltaic (PV) projects in Ontario, Canada, through its subsidiary, Solar Flow-Through General Partnership. Working with Solar Flow-Through, the Company has also developed a flow-through investment vehicle for investors to participate in Ontario's solar energy growth.
Employees
-